OptiNose’s innovative approach is designed to enable drug delivery deep in the nasal cavity, leveraging the mucosal surfaces as a potent target for the treatment of both local and systemic diseases. Known as Bi-Directional™ Breath Powered® Exhalation Delivery System, the OptiNose platform can potentially offer an alternative to conventional treatments. LEARN MORE »
See how it works
OptiNose’s candidates include OPN-375 and AVP-825 being developed for Nasal Polyposis and Acute Migraine, respectively. We have also identified more than ten pipeline candidates that we believe hold outstanding potential to help patients using our Bi-Directional Breath Powered Exhalation Delivery System. VIEW CANDIDATES »
News & Media Coverage
September 19, 2016 | News
New Research Highlights the Burden of Illness Suffered by Chronic Rhinosinusitis Patients
September 16, 2016 | News
OptiNose Presents Data from Phase 3 Trials with Investigational Product Using Exhalation Delivery Sy...
February 01, 2016 | News
OptiNose® Announces Pipeline Project to Evaluate Nose-to-Brain Application of Bi-Directional™ Bre...